Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical TrialPRNewsWire • 07/01/20
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdatePRNewsWire • 06/12/20
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints AchievedPRNewsWire • 06/10/20